Observing Safety and Treatment Patterns in Early Alzheimers Disease Patients Using Lecanemab A Multicenter Postmarketing Study on Amyloid Related Imaging Abnormalities

What this Trial Is About

Researchers are studying the characteristics of amyloid related imaging abnormalities ARIA and how treatment with lecanemab continues or changes after ARIA onset in people with early Alzheimers disease. This observational study focuses on participants receiving lecanemab as part of their routine medical care. The goal is to better understand safety and treatment patterns in real-world settings. Participants prescribed lecanemab by their doctor will be followed for up to 156 weeks or until they stop treatment. This is a non-interventional study, meaning participants receive lecanemab as part of usual care without additional treatments or procedures from the study. The research observes participants over time without altering their prescribed therapies. During the study, researchers will monitor for ARIA types including oedemaeffusion and microhemorrhages. They will also track any interruptions or discontinuations of lecanemab after ARIA occurs, as well as any infusion-related reactions. Participants may have assessments at regular intervals during the observation period. The total participation time can last up to three years, reflecting long-term monitoring in clinical practice.

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab